<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04703413</url>
  </required_header>
  <id_info>
    <org_study_id>LOF-0036</org_study_id>
    <nct_id>NCT04703413</nct_id>
  </id_info>
  <brief_title>User Satisfaction When Catheterizing With Hydrophilic Urinary Catheters From a More Sustainable Manufacturing Process.</brief_title>
  <official_title>User Satisfaction When Catheterizing With Hydrophilic Urinary Catheters From a More Sustainable Manufacturing Process. An Open, Prospective, Post-market Clinical Follow-up Investigation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dentsply International</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wellspect HealthCare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dentsply International</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open, prospective, single arm, multicenter clinical investigation. All subjects will use&#xD;
      the investigational device for 30 days each.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 17, 2020</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjects' satisfaction, when practicing IC (insertion/withdrawal) using study device.</measure>
    <time_frame>30 days</time_frame>
    <description>The subject's assessment of satisfaction using a five-level scale in a pPRO (Wellspect Follow-up questionnaire): How satisfied have you been with the catheterization (insertion/withdrawal) when using the investigational device?&#xD;
= completely unsatisfied&#xD;
= unsatisfied&#xD;
= neutral&#xD;
= satisfied&#xD;
= completely satisfied</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reason for dissatisfaction (if any) when practicing IC with study device.</measure>
    <time_frame>30 days</time_frame>
    <description>The proportion of subjects that are unsatisfied/completely unsatisfied and specifying the reason in free text. pPRO (Wellspect questionnaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Experience of any problems before, during and after catheterization with investigational device.</measure>
    <time_frame>30 days</time_frame>
    <description>The proportion of subjects that experienced any problems. A yes/no scale, if yes, a specification (free text) is required.&#xD;
pPRO (Wellspect questionnaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Catheter usability (incl. ease of use) when practicing IC with investigational device.</measure>
    <time_frame>30 days</time_frame>
    <description>The mean of all subject's answers/domain score of ISC-Q (ease of use) completed at the end of investigation visits. pPRO (Wellspect questionnaire) and ISC-Q - domain ease of use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL when practicing IC with investigational device.</measure>
    <time_frame>30 days</time_frame>
    <description>ISC-Q total mean score The mean of all subjects' total score of ISC-Q completed at the end of investigation visits.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Bladder Voiding Dysfunction</condition>
  <arm_group>
    <arm_group_label>LoFric® OrigoTM or LoFric® SenseTM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydrophilic male (LoFric Origo) and female (LoFric Sense) urinary catheters for single use. Target subject population are subjects suffering from bladder voiding dysfunction and are experienced in intermittent catheterization (IC).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LoFric® OrigoTM and LoFric® SenseTM</intervention_name>
    <description>The investigational device is either a CE-marked LoFric® OrigoTM , 40 cm, CH12/CH14 or LoFric® SenseTM, 15 cm, CH12. They are all intermittent urinary catheters with a Nelaton tip from a more sustainable manufacturing process. All subjects will use the investigational device for 30 days each.</description>
    <arm_group_label>LoFric® OrigoTM or LoFric® SenseTM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For inclusion in the study, subjects must fulfil all of the following criteria:&#xD;
&#xD;
          1. Provision of informed consent i.e. subject must be able to understand and sign the&#xD;
             Informed Consent Form&#xD;
&#xD;
          2. Aged 18 years and over, both gender&#xD;
&#xD;
          3. Bladder dysfunction, all diagnosis practicing IC at least 2 times daily&#xD;
&#xD;
          4. Using catheters in the sizes available in the investigation (15 cm, CH 12 or 40 cm CH&#xD;
             12/14, Nelaton tip)&#xD;
&#xD;
          5. Experienced users of IC defined as a minimum of 4 weeks on therapy prior investigation&#xD;
             start&#xD;
&#xD;
          6. Adults able to read, write and understand information given to them regarding the&#xD;
             investigation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Any of the following is regarded as a criterion for exclusion from the study:&#xD;
&#xD;
          1. Ongoing, symptomatic UTI at enrolment as judged by investigator. The definition of&#xD;
             UTI, is a positive urine culture of ≥103 CFU/ml of ≥1 bacterial species and presence&#xD;
             of symptoms or signs compatible with UTI with no other identified source of infection.&#xD;
&#xD;
          2. Known urethral stricture which, in the opinion of the investigator, could influence&#xD;
             the subject's evaluation of the catheters.&#xD;
&#xD;
          3. Involvement in the planning and conduct of the investigation (applies to both&#xD;
             Wellspect/site staff).&#xD;
&#xD;
          4. Previous enrolment in the present investigation.&#xD;
&#xD;
          5. Simultaneous participation in another clinical investigation that may impact the&#xD;
             primary endpoint.&#xD;
&#xD;
          6. Expected or severe non-compliance to the CIP as judged by the investigator and/or&#xD;
             Wellspect.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus Wittebo, M.Sc. Pharm.</last_name>
    <role>Study Director</role>
    <affiliation>Wellspect HealthCare</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ruth Kirschner-Hermanns, Univ.-Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Bonn, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Albert Kaufmann, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zentrum für Kontinenz und Neuro-Urologie, Kliniken Maria Hilf GmbH, Mönchengladbach</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Markus Wittebo</last_name>
    <phone>+46 31 376 40 00</phone>
    <email>Markus.Wittebo@wellspect.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Leitung der Neuro-Urologie Klinik der Urologie und Kinderurologie Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruth Kirschner-Hermanns, Univ.-Prof. Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zentrum für Kontinenz und Neuro-Urologie Kliniken Maria Hilf GmbH Akademisches Lehrkrankenhaus der Uniklinik RWTH Aachen, Mönchengladbach</name>
      <address>
        <city>Mönchengladbach</city>
        <zip>41063</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Albert Kaufmann, Dr. med.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 7, 2021</study_first_submitted>
  <study_first_submitted_qc>January 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2021</study_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

